F13A1 rs1799984: Understanding the Val34Leu Variant
The rs1799984 variant, commonly known as Val34Leu, is a genetic change in the F13A1 gene that affects the structure and activation of coagulation factor XIII. Research has investigated its potential role in influencing the risk of conditions like venous thromboembolism and myocardial infarction, though findings remain inconsistent.
What each genotype means
Typical factor XIII activity
This genotype represents the most common form of the F13A1 gene, often referred to as the Val34/Val34 genotype. Research indicates that individuals with this genotype do not carry the leucine substitution that is associated with altered fibrin clot structure and potential protection against certain clotting disorders.
This is the most common genotype in most populations, though its frequency varies significantly by ancestry.
Increased factor XIII activation
This genotype, often referred to as Val34/Leu34, results in the production of a factor XIII protein that may have an increased activation rate. Some studies suggest this variant may offer a modest protective effect against venous thromboembolism, though findings across different cardiovascular conditions remain inconsistent and sometimes conflicting.
Carried by a significant portion of the population, with the minor allele frequency reaching approximately 0.20 to 0.25 in European populations.
Increased factor XIII activation
This genotype, often referred to as Leu34/Leu34, is associated with an increased rate of factor XIII activation and altered fibrin clot structure. While some research suggests a protective association against venous thromboembolism, other studies have reported conflicting results regarding its impact on stroke and heart disease risk, indicating that the clinical significance is not fully established.
This genotype is less common than the heterozygous form, occurring at a frequency consistent with the minor allele frequency of approximately 0.20 to 0.25 in European populations.
What is the rs1799984 Variant?
The rs1799984 variant is a single nucleotide polymorphism (SNP) located within the F13A1 gene. This specific genetic change results in a missense mutation where the amino acid valine is replaced by leucine at position 34 of the factor XIII-A subunit protein. Because this position is located near the thrombin activation site, the substitution can alter how quickly the protein is activated during the blood coagulation process. Scientists study this variant because it is a common genetic change that may influence the physical properties of fibrin clots, which are the mesh-like structures that stop bleeding. While the variant is well-documented in genetic databases, its functional impact on human health is a subject of ongoing scientific inquiry rather than a definitive predictor of disease.
The Role of the F13A1 Gene
The F13A1 gene provides the instructions for creating the A subunit of coagulation factor XIII. Factor XIII is a critical protein in the final stages of the blood clotting cascade, acting as a transglutaminase that stabilizes fibrin clots by cross-linking fibrin monomers. By strengthening these clots, factor XIII ensures they are resistant to premature breakdown, a process known as fibrinolysis. When the F13A1 gene functions normally, it helps maintain a balance between preventing excessive bleeding and avoiding unnecessary clotting. Because factor XIII is essential for clot integrity, researchers have long hypothesized that variations in the gene, such as rs1799984, might influence an individual's susceptibility to thrombotic events, such as heart attacks or deep vein thrombosis, by changing the rate at which these stable clots are formed.
Research and Evidence Strength
The evidence linking rs1799984 to clinical outcomes is considered limited and often conflicting. Early studies suggested that the Leu allele might offer a protective effect against venous thromboembolism and myocardial infarction by altering clot structure. However, subsequent research has produced mixed results, with some large-scale studies failing to find a significant association between this variant and cardiovascular disease risk. Factors such as age, ethnicity, and the presence of other cardiovascular risk factors often complicate these findings. Because the results are inconsistent across different populations and study designs, the scientific community does not currently view this variant as a reliable clinical marker for predicting heart disease or stroke. It remains a topic of academic interest rather than a standard diagnostic tool.
Population Frequency
The frequency of the rs1799984 variant varies significantly depending on ancestral background. In European populations, the minor allele frequency is typically observed between 0.20 and 0.25, making it a relatively common genetic variation. In contrast, the variant is much less common in East Asian populations, where the minor allele frequency is often reported at less than 0.03. These differences highlight the importance of considering ancestry when interpreting genetic data. Because the variant is common in some groups but rare in others, researchers must be careful to account for population structure in their studies to avoid misleading conclusions about the variant's impact on health.
Interpreting Your Genetic Information
If you have information about your rs1799984 genotype, it is important to understand that this variant is not a diagnostic test for any medical condition. Genetic associations are statistical observations made across large groups of people and do not necessarily apply to an individual's specific health trajectory. Many factors, including lifestyle, environment, and other genetic markers, play a much larger role in determining your risk for cardiovascular issues. You should never use this information to make decisions about your health or medication without consulting a qualified healthcare professional. If you have concerns about blood clotting or cardiovascular health, speak with your doctor or a genetic counselor who can provide context based on your full medical history and clinical symptoms.
How common is this variant?
The minor allele frequency for rs1799984 is approximately 0.20-0.25 in European populations, while it is significantly lower, often below 0.03, in East Asian populations.
Frequently asked questions
Is rs1799984 a cause of heart disease?
No, rs1799984 is not considered a direct cause of heart disease. While some studies have explored its potential association with cardiovascular risk, the evidence is inconsistent and not strong enough to establish a causal link.
Should I be worried if I have the variant?
There is no reason for concern based on this variant alone. Genetic variants are common, and most do not have a significant impact on your daily health or disease risk.
Does this variant affect how I should take blood thinners?
There is no standard clinical guidance suggesting that this variant should change how you take medication. Always discuss your medication dosing and any health concerns with your doctor or pharmacist.
Where can I find more information about F13A1?
You can find reliable information about the F13A1 gene and its associated variants on resources like MedlinePlus Genetics, the NCBI Gene database, and ClinVar.
Sources & further reading
Educational information only, last refreshed 10/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1799984?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in F13A1
The Val34Leu missense change accelerates factor XIII activation, imparting protection against venous thromboembolism while altering fibrin clot stability.
Missense alteration (p.Leu34Phe) in coagulation factor XIII A1 subunit modifying clot stability and venous thromboembolism risk.